Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, 1230 N Cherry Avenue, PO Box 210242, Tucson, AZ, 85719, USA.
Curr Allergy Asthma Rep. 2019 Sep 5;19(10):45. doi: 10.1007/s11882-019-0881-3.
Asthma is a common inflammatory airway disease, which affects more than 300 million people worldwide. Although conventional drugs are effective for most of the patients with mild-to-moderate asthma, they are less effective for patients with difficult-to-treat or severe asthma. Identification of asthma endotypes and biomarkers will lead to more precise approaches to treat asthma.
Asthma subphenotypes and endotypes have been described based on clinical variables and sputum granulocytes. A recent asthma endotype study has been summarized based on the combination of T2 (FeNO) and non-T2 (IL-6) biomarkers. Discovery of potential biomarkers for asthma has been discussed in the context of omics approaches. Current biologic drugs for asthma have been summarized, and the future direction of precise treatment of asthma has been suggested. This review provides a concise overview of the current state of subphenotypes, endotypes, biomarkers, omics approaches, and biologic drugs in asthma.
哮喘是一种常见的气道炎症性疾病，影响着全球超过 3 亿人。尽管常规药物对大多数轻中度哮喘患者有效，但对治疗棘手或重度哮喘患者的效果较差。鉴定哮喘的亚型和生物标志物将导致更精确的哮喘治疗方法。
根据临床变量和痰液中的粒细胞，已经描述了哮喘亚表型和内表型。最近的一项哮喘内表型研究是基于 T2（FeNO）和非 T2（IL-6）生物标志物的组合进行总结的。本文还讨论了通过组学方法发现哮喘潜在生物标志物的情况。目前已经对哮喘的生物药物进行了总结，并提出了精确治疗哮喘的未来方向。这篇综述简要概述了哮喘的亚表型、内表型、生物标志物、组学方法和生物药物的现状。
